TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 18, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 14.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 18, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| December 30, 2026 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | Trial Milestone | Phase 1 |
| June 15, 2029 | A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation | Trial Milestone | Phase 3 |
Track TCRX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open TCRX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.